{"id":"https://openalex.org/W76278028","doi":null,"title":"Clindamycin phosphate 1.2%-benzoyl peroxide (5% or 2.5%) plus tazarotene cream 0.1% for the treatment of acne.","display_name":"Clindamycin phosphate 1.2%-benzoyl peroxide (5% or 2.5%) plus tazarotene cream 0.1% for the treatment of acne.","publication_year":2013,"publication_date":"2013-02-01","ids":{"openalex":"https://openalex.org/W76278028","mag":"76278028","pmid":"https://pubmed.ncbi.nlm.nih.gov/23513559"},"language":"en","primary_location":{"id":"pmid:23513559","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/23513559","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Cutis","raw_type":"Comparative Study"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5087638193","display_name":"Sunil Dhawan","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Sunil S Dhawan","raw_affiliation_strings":["Center for Dermatology Clinical Research Inc, 2557 Mowry Ave, Ste 25, Fremont, CA 94538, USA. sdhaw@yahoo.com"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Center for Dermatology Clinical Research Inc, 2557 Mowry Ave, Ste 25, Fremont, CA 94538, USA. sdhaw@yahoo.com","institution_ids":[]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5054126573","display_name":"Jennifer Gwazdauskas","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Jennifer Gwazdauskas","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]}],"institutions":[],"countries_distinct_count":0,"institutions_distinct_count":0,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":0.3521,"has_fulltext":false,"cited_by_count":8,"citation_normalized_percentile":{"value":0.59960532,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":88,"max":95},"biblio":{"volume":"91","issue":"2","first_page":"99","last_page":"104"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11553","display_name":"Acne and Rosacea Treatments and Effects","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2708","display_name":"Dermatology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T11553","display_name":"Acne and Rosacea Treatments and Effects","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2708","display_name":"Dermatology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10837","display_name":"Dermatology and Skin Diseases","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2708","display_name":"Dermatology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11172","display_name":"Dermatologic Treatments and Research","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2708","display_name":"Dermatology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/acne-vulgaris","display_name":"acne","score":0.9229999780654907},{"id":"https://openalex.org/keywords/clindamycin-phosphate","display_name":"clindamycin phosphate","score":0.902999997138977},{"id":"https://openalex.org/keywords/benzoyl-peroxide","display_name":"benzoyl peroxide","score":1.0},{"id":"https://openalex.org/keywords/tazarotene","display_name":"tazarotene","score":0.9980000257492065},{"id":"https://openalex.org/keywords/topical-gel","display_name":"topical gel","score":0.5090000033378601},{"id":"https://openalex.org/keywords/combination-therapy","display_name":"combination therapy","score":0.6269999742507935},{"id":"https://openalex.org/keywords/adjuvant-therapy","display_name":"adjuvant therapy","score":0.8100000023841858},{"id":"https://openalex.org/keywords/facial-acne","display_name":"facial acne","score":0.7429999709129333},{"id":"https://openalex.org/keywords/tolerability","display_name":"tolerability","score":0.8330000042915344},{"id":"https://openalex.org/keywords/efficacy","display_name":"efficacy","score":0.5220000147819519},{"id":"https://openalex.org/keywords/quality-of-life","display_name":"quality of life","score":0.7850000262260437},{"id":"https://openalex.org/keywords/once-daily-application","display_name":"once-daily application","score":0.6000000238418579}],"concepts":[{"id":"https://openalex.org/C2778375690","wikidata":"https://www.wikidata.org/wiki/Q7814214","display_name":"Tolerability","level":3,"score":0.9673475027084351},{"id":"https://openalex.org/C2778885487","wikidata":"https://www.wikidata.org/wiki/Q411424","display_name":"Benzoyl peroxide","level":4,"score":0.9070566892623901},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.8740483522415161},{"id":"https://openalex.org/C2777673923","wikidata":"https://www.wikidata.org/wiki/Q79928","display_name":"Acne","level":2,"score":0.8098849058151245},{"id":"https://openalex.org/C2779306117","wikidata":"https://www.wikidata.org/wiki/Q3981685","display_name":"Tazarotene","level":3,"score":0.7420518398284912},{"id":"https://openalex.org/C2777863537","wikidata":"https://www.wikidata.org/wiki/Q357896","display_name":"Adjuvant","level":2,"score":0.5705346465110779},{"id":"https://openalex.org/C2777458120","wikidata":"https://www.wikidata.org/wiki/Q422273","display_name":"Clindamycin","level":3,"score":0.5362706780433655},{"id":"https://openalex.org/C16005928","wikidata":"https://www.wikidata.org/wiki/Q171171","display_name":"Dermatology","level":1,"score":0.5222440361976624},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.3420614004135132},{"id":"https://openalex.org/C197934379","wikidata":"https://www.wikidata.org/wiki/Q2047938","display_name":"Adverse effect","level":2,"score":0.2822442948818207},{"id":"https://openalex.org/C501593827","wikidata":"https://www.wikidata.org/wiki/Q12187","display_name":"Antibiotics","level":2,"score":0.18257248401641846},{"id":"https://openalex.org/C521977710","wikidata":"https://www.wikidata.org/wiki/Q81163","display_name":"Polymer","level":2,"score":0.0},{"id":"https://openalex.org/C185592680","wikidata":"https://www.wikidata.org/wiki/Q2329","display_name":"Chemistry","level":0,"score":0.0},{"id":"https://openalex.org/C89423630","wikidata":"https://www.wikidata.org/wiki/Q7193","display_name":"Microbiology","level":1,"score":0.0},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.0},{"id":"https://openalex.org/C178790620","wikidata":"https://www.wikidata.org/wiki/Q11351","display_name":"Organic chemistry","level":1,"score":0.0},{"id":"https://openalex.org/C44228677","wikidata":"https://www.wikidata.org/wiki/Q181898","display_name":"Polymerization","level":3,"score":0.0}],"mesh":[{"descriptor_ui":"D000152","descriptor_name":"Acne Vulgaris","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D000287","descriptor_name":"Administration, Topical","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000293","descriptor_name":"Adolescent","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000328","descriptor_name":"Adult","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D001585","descriptor_name":"Benzoyl Peroxide","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D001585","descriptor_name":"Benzoyl Peroxide","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D002648","descriptor_name":"Child","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D002981","descriptor_name":"Clindamycin","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D002981","descriptor_name":"Clindamycin","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D003879","descriptor_name":"Dermatologic Agents","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D003879","descriptor_name":"Dermatologic Agents","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D004338","descriptor_name":"Drug Combinations","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D005145","descriptor_name":"Face","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D005260","descriptor_name":"Female","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D005782","descriptor_name":"Gels","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008297","descriptor_name":"Male","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D009539","descriptor_name":"Nicotinic Acids","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D009539","descriptor_name":"Nicotinic Acids","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D009824","descriptor_name":"Ointments","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D011788","descriptor_name":"Quality of Life","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D011795","descriptor_name":"Surveys and Questionnaires","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D012176","descriptor_name":"Retinoids","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D012720","descriptor_name":"Severity of Illness Index","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D016009","descriptor_name":"Chi-Square Distribution","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D016037","descriptor_name":"Single-Blind Method","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D016896","descriptor_name":"Treatment Outcome","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D018709","descriptor_name":"Statistics, Nonparametric","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false}],"locations_count":2,"locations":[{"id":"pmid:23513559","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/23513559","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Cutis","raw_type":"Comparative Study"},{"id":"mag:76278028","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/23513559","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":null,"is_accepted":false,"is_published":false,"raw_source_name":"PubMed","raw_type":null}],"best_oa_location":null,"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","score":0.9940000176429749,"display_name":"Good health and well-being"}],"study_designs":[{"id":"https://openalex.org/study-designs/randomized-controlled-trial","display_name":"Randomized Controlled Trial"},{"id":"https://openalex.org/study-designs/clinical-trial","display_name":"Clinical Trial"}],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2039884403","https://openalex.org/W2411059349","https://openalex.org/W2117050203","https://openalex.org/W1920031359","https://openalex.org/W2414916033","https://openalex.org/W2340625650","https://openalex.org/W2808104094","https://openalex.org/W2195557333","https://openalex.org/W2415970565","https://openalex.org/W4250662886"],"abstract_inverted_index":{"Acne":[0],"is":[1],"a":[2,80],"multifactorial":[3],"chronic":[4],"dermatosis":[5],"that":[6,162],"can":[7],"be":[8],"effectively":[9],"treated":[10],"with":[11,46,64,136,170],"adjuvant":[12,28],"medications.":[13],"The":[14],"objective":[15],"of":[16,26,152,180],"our":[17],"study":[18,82,160],"was":[19,128],"to":[20,66,74,182,192],"compare":[21],"the":[22,123,132,137,148],"tolerability":[23,105],"and":[24,83,96,177],"efficacy":[25],"2":[27],"therapies":[29],"combining":[30],"clindamycin":[31,38],"phosphate":[32,39],"1.2%-benzoyl":[33,40],"peroxide":[34,41],"5%":[35],"(CLNP-BPO5)":[36],"or":[37,77,155,164],"2.5%":[42],"(CLNP-BPO2.5)":[43],"fixed-dose":[44,166],"gels":[45,167],"tazarotene":[47],"(TZ)":[48],"cream":[49,172],"0.1%":[50,173],"(CLNP-BPO5/TZ":[51],"vs":[52],"CLNP-BPO2.5/TZ)":[53],"when":[54,186],"applied":[55,187],"topically":[56],"once":[57,188],"daily":[58,189],"for":[59,147,190],"12":[60,97,193],"weeks":[61,91],"in":[62,79,126,131,168],"participants":[63,71],"moderate":[65,181],"severe":[67,183],"facial":[68,184],"acne.":[69],"Forty":[70],"were":[72,84,145],"randomized":[73],"receive":[75],"CLNP-BPO5/TZ":[76,133],"CLNP-BPO2.5/TZ":[78,138],"parallel-group":[81],"evaluated":[85],"at":[86,99],"baseline":[87,115],"as":[88,90],"well":[89],"1,":[92],"2,":[93],"4,":[94,122],"8,":[95],"(or":[98],"early":[100],"termination).":[101],"In":[102],"both":[103],"groups,":[104],"assessments":[106],"increased":[107],"by":[108,117],"week":[109,118,121],"1":[110],"but":[111],"gradually":[112],"returned":[113],"toward":[114],"levels":[116],"12.":[119],"At":[120],"mean":[124],"change":[125],"burning/stinging":[127],"significantly":[129],"higher":[130],"group":[134,139],"compared":[135],"(P<.05).":[140],"No":[141],"other":[142],"significant":[143],"differences":[144],"observed":[146],"tolerability,":[149],"efficacy,":[150],"quality":[151],"life":[153],"(QOL),":[154],"participant":[156],"preference":[157],"assessments.":[158],"Our":[159],"shows":[161],"CLNP-BPO5":[163],"CLNP-BPO2.5":[165],"combination":[169],"TZ":[171],"are":[174],"generally":[175],"well-tolerated":[176],"effective":[178],"treatments":[179],"acne":[185],"up":[191],"weeks.":[194]},"counts_by_year":[{"year":2022,"cited_by_count":2},{"year":2020,"cited_by_count":2},{"year":2019,"cited_by_count":2},{"year":2017,"cited_by_count":1},{"year":2015,"cited_by_count":1}],"updated_date":"2026-10-31T12:09:11.096373","created_date":"2016-06-24T00:00:00"}